Achaogen Stock

Stocks

AKAOQ

US0044491043

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Achaogen -.--% +278.79%

Valuation: Achaogen

Market Cap 639K 562K 522K 480K 900K 61.86M 916K 6.24M 2.43M 30.17M 2.4M 2.35M 105M P/E 2017
-3.39x
P/E 2018 -0.29x
Enterprise Value 19.47M 17.12M 15.91M 14.63M 27.43M 1.89B 27.93M 190M 74.19M 920M 73.08M 71.5M 3.19B EV / Sales 2017
28x
EV / Sales 2018 8.66x
Free-Float
-
Yield 2017 *
-
Yield 2018 -

Financials

2017 2018
Net sales 11.18M 9.83M 9.13M 8.4M 15.75M 1.08B 16.03M 109M 42.59M 528M 41.95M 41.05M 1.83B 8.73M 7.68M 7.13M 6.56M 12.3M 845M 12.52M 85.28M 33.26M 412M 32.77M 32.06M 1.43B
Net income -126M -110M -103M -94.4M -177M -12.17B -180M -1.23B -479M -5.93B -472M -461M -20.59B -187M -164M -152M -140M -263M -18.06B -268M -1.82B -711M -8.81B -700M -685M -30.56B
Net Debt -143M -126M -117M -107M -201M -13.83B -205M -1.4B -544M -6.75B -536M -525M -23.41B 18.83M 16.56M 15.38M 14.15M 26.53M 1.82B 27.01M 184M 71.75M 889M 70.68M 69.16M 3.09B
Logo Achaogen
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. AKAOQ Stock